---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-26-000034"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2026-06-05T20:14:05+00:00"
generated_at: "2026-06-05T20:23:33.687520+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Xeris shareholders elect Halkuff and Johnson as directors; approve auditor and say-on-pay

## Summary
- Dawn Halkuff elected with 62.6M for, 24.9M withhold; John Johnson with 52.7M for, 34.8M withhold.
- Auditor Ernst & Young ratified for FY2026 with 125.8M for, 1.0M against, 1.4M abstain.
- Advisory say-on-pay approved with 82.2M for, 4.7M against, 0.6M abstain; broker non-votes 40.8M.
- Meeting quorum of 128.3M shares from 172.6M outstanding.

## SEC filing metadata
- accession: 0001867096-26-000034
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2026-06-05T20:14:05+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000034/0001867096-26-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000034/xers-20260604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-26-000034
- JSON: https://secwatch.observer/filing/0001867096-26-000034.json
- Plain text: https://secwatch.observer/filing/0001867096-26-000034.txt

## Key facts
- Shareholder Votes
  Xeris Biopharma Holdings, Inc. shareholders approved Election of Directors at the 2026-06-04 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: Each nominee was elected by a plurality vote in accordance with the Company’s Amended and Restated Bylaws, as follows: Class II Director Nominee For Withhold Broker Non-Votes Dawn Halkuff 62,581,577 24,906,166 40,780,330 John Johnson 52,665,077 34,822,666 40,780,330
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000034/0001867096-26-000034-index.htm
- Shareholder Votes
  Xeris Biopharma Holdings, Inc. shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2026-06-04 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the “Say-on-Pay Vote”). The Company’s stockholders voted as follows to approve such executive compensation for the Company’s named executive officers pursuant to the Say-on-Pay Vote: For Against Abstain Broker Non-Votes 82,230,204 4,658,035 599,504 40,780,330
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000034/0001867096-26-000034-index.htm
- Shareholder Votes
  Xeris Biopharma Holdings, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstain Broker Non-Votes 125,789,818 1,032,530 1,445,725 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000034/0001867096-26-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.